| MORPHOSYS AG O.N. | 117.0000 / -0.76% |
| Date/Time | 07/08 / 08:01 |
| Chg. / Chg.(%) | -0.9000 / -0.76% |
| Bid | 118.3500 / 100 |
| Ask | 118.4500 / 100 |
| Open | 117.0000 |
| Previous Close | 117.9000 |
| High | 117.0000 |
| Low | 117.0000 |
| Volume [EUR] | 0.0000 |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Frankfurt |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 118.30 |  |
32,418 |
| Cboe Europe .. | 118.35 | |
19,654 |
| TradeGate | 118.250 |  |
2,937 |
| Cboe Europe .. | 118.35 | |
2,823 |
| Turquoise | 118.35 | |
1,948 |
| London Inter.. | 118.40 | |
1,041 |
| Vienna Globa.. | 117.40 | |
0 |
| Frankfurt | 117.0000 | |
0 |
| Hannover | 116.55 | |
0 |
| Berlin | 116.65 | |
0 |
| München | 117.00 | |
0 |
| Hamburg | 116.55 | |
0 |
| Düsseldorf | 116.60 | |
0 |
| Lang & Schwa.. | 118.300 | |
|
| gettex | 118.250 | |
|
| Stuttgart | 118.150 | |
|
| SIX Swiss Ex.. | 102.00 | ||
| Nasdaq Other.. | 128.1500 | 100 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
09/13/2018 / 22:04 - GlobeNewswire
Real-time